Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2011-06-03

FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for EXFORGE HCT (amlodipine/valsartan/hydrochlorothiazide) from Novartis, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for EXFORGE HCT (AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE)